Table 2.
Comparison of Clinical Recipient and Donor Characteristics at Time of Transplant Among Liver Transplant Recipients With Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
| Characteristic | HIV/HCV LT Recipients | |||
|---|---|---|---|---|
| Overall (N = 286) |
Pre-DAA (n = 166) |
DAA (n = 120) |
P Value | |
| Age at transplant, y, median (IQR) | 56 (49–62) | 55 (49–61) | 58 (50–64) | <.001 |
| Age, y | ||||
| ȃ<40 | 15 (5.2) | 12 (7.2) | 3 (2.5) | .077 |
| ȃ40–49 | 61 (21.3) | 46 (27.7) | 15 (12.5) | .002 |
| ȃ50–65 | 187 (65.4) | 106 (63.9) | 81 (67.5) | .523 |
| ȃ>65 | 23 (8.0) | 2 (1.2) | 21 (17.5) | <.001 |
| Gender | ||||
| ȃFemale | 58 (20.3) | 27 (16.3) | 31 (25.8) | .047 |
| ȃMale | 228 (79.7) | 139 (83.7) | 89 (74.2) | .047 |
| Ethnicity/race | ||||
| ȃWhite | 165 (57.7) | 104 (62.7) | 61 (50.8) | .046 |
| ȃBlack/African American | 62 (21.7) | 36 (21.7) | 26 (21.7) | .997 |
| ȃHispanic/Latino | 50 (17.5) | 24 (14.5) | 26 (21.7) | .113 |
| ȃAsian | 5 (1.8) | 2 (1.2) | 3 (2.5) | .410 |
| Etiology of liver disease | ||||
| ȃAlcohol-related liver disease | 4 (1.4) | 2 (1.2) | 2 (1.7) | .743 |
| ȃNonalcoholic steatohepatitis | 2 (0.7) | 0 | 2 (1.7) | .095 |
| ȃHepatocellular carcinoma | 84 (29.4) | 32 (19.3) | 52 (43.3) | <.001 |
| Diabetes | 49 (17.1) | 30 (18.1) | 19 (15.8) | .620 |
| Obesity (BMI >30 kg/m2) | 68 (23.8) | 33 (19.9) | 35 (29.2) | .069 |
| BMI <18.5 kg/m2 | 3 (1.1) | 2 (1.2) | 1 (0.8) | .761 |
| Hepatic decompensation at transplant | ||||
| ȃSevere hepatic encephalopathy | 23 (8.0) | 18 (10.8) | 5 (4.2) | .040 |
| ȃModerate ascites | 57 (19.9) | 40 (24.1) | 17 (14.2) | .038 |
| ȃDialysis | 9 (3.2) | 5 (3.0) | 4 (3.3) | .878 |
| ȃPortal venous thrombosis | 24 (8.4) | 9 (5.4) | 15 (12.5) | .033 |
| ȃHistory of SBP | 18 (6.3) | 14 (8.4) | 4 (3.3) | .080 |
| Laboratory MELD score at LT, median (IQR) | 17 (12–25) | 16 (11–22) | 19 (12–28) | .011 |
| Wait time to LT, mo, median (IQR) | 4.1 (0.6–11.8) | 3 (0.5–8.9) | 6.7 (1.0–13) | .029 |
| Recipient HBsAg positive | 18 (6.3) | 12 (7.2) | 6 (5.0) | .444 |
| Donor CMV IgG+/recipient CMV IgG– | 14 (4.9) | 13 (7.8) | 1 (0.8) | .007 |
| Donor EBV IgG+/recipient EBV IgG– | 14 (4.9) | 10 (6.0) | 4 (3.3) | .298 |
| Donor characteristics | ||||
| ȃAge, y, median (IQR) | 42 (27–54) | 43 (26–54) | 41 (28–54) | .268 |
| ȃBlack/African American | 60 (21.0) | 37 (22.3) | 23 (19.2) | .522 |
| ȃCold ischemia time, h, median (IQR) | 6.0 (4.8–7.8) | 6.0 (5.0–7.9) | 5.8 (4.7–7.7) | .268 |
| ȃHCV antibody positive | 42 (14.7) | 13 (7.8) | 29 (24.2) | <.001 |
| ȃHIV positive | 13 (4.6) | 3 (1.8) | 10 (8.3) | .009 |
| ȃHistory of drug use | 122 (42.7) | 55 (33.1) | 67 (55.8) | <.001 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CMV, cytomegalovirus; DAA, direct-acting antiviral; EBV, Epstein-Barr virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; IQR, interquartile range; LT, liver transplant; MELD, Model for End-Stage Liver Disease; SBP, spontaneous bacterial peritonitis.